Adenosine monophosphate
|
Basic information |
| Metabolite name | Adenosine monophosphate |
 | HMDB0000045 |
 |
C00020 |
 |
6083 |
| Synonyms | adenosine-5-monophosphate; |
| No. of studies | 22 |
|
Basic information |
| Metabolite name | Adenosine monophosphate |
| HMDB0000045 |
|
C00020 |
|
6083 |
| Synonyms | adenosine-5-monophosphate; |
| No. of studies | 22 |
|
Relationship between Adenosine monophosphate and depression (count: 22) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type3 | venlafaxine group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Up |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M863 | Type2 | CSDS+ edaravone group vs. CSDS group | Hippocampus | C57BL/6J mouse | Up |
| Study M863 | Type2 | CSDS+ edaravone group vs. CSDS group | Medial prefrontal cortex | C57BL/6J mouse | Up |
| Study M869 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M869 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M869 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M957 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Down |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |